Category Archives: Autologous

Lete-cel’s Readout Anticipated For 2023; New GSK Expected to Launch by Mid-2022; GSK’s Q4 2021 Earnings Call Summary

On Wednesday, February 9, GSK held their Q4 2021 earnings call (press release / presentation). Of note, management presented lete-cel’s (NY-ESO-1 TCR-T) upcoming clinical updates and highlighted that GSK’s business separation is anticipated by mid-2022. Below, Celltelligence provides insights on potential approval timelines for lete-cel and how it compares to Adaptimmune’s afami-cel (MAGE-A4 SPEAR-T).

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Breyanzi’s Sales Increase While Abecma’s Remain Flat; How Will BMS Meet CAR-T Manufacturing Demand? Breyanzi On Track for EU Approval in 2L LBCL; BMS’s Q4 2021 Earnings Call Summary

On Friday, February 4, BMS held their Q4 2021 earnings call (press release / presentation) highlighting their manufacturing supply strategy for the anticipated increase in demand of Breyanzi (CD19 CAR-T) and Abecma (BCMA CAR-T). Below, Celltelligence provides insights on the potential challenges BMS may encounter expanding into earlier lines of therapy and additional geographies.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Kymriah Sales Continue to Decline; Could an Approval in FL Offset Kymriah’s Revenue Loss in DLBCL? Novartis’s Q4 2021 Earnings Call Summary

On Wednesday, February 2, Novartis held their Q4 2021 earnings call (press release / presentation) highlighting Kymriah’s (CD19 CAR-T) quarterly sales decline and regulatory submission in Japan for r/r FL. Below, Celltelligence provides insights on Kymriah’s Q4 2021 revenue, while discussing if Kymriah’s upcoming approvals in r/r FL will be enough to offset declining sales.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Yescarta’s Sales Grow; Gilead Prepares for Increased Manufacturing Demands; Tecartus’s EU Approval in R/R Adult ALL Faces Delays; Gilead’s Q4 2021 Earnings Call Summary

On Tuesday, February 1, Gilead held their Q4 2021 earnings call (press release / presentation) highlighting an increase in revenue for their cell therapy franchise and Yescarta’s anticipated approval in 2L r/r LBCL. Furthermore, management highlighted Tecartus’s (CD19 CAR-T) Type II variation in the EU for r/r adult ALL. Below, Celltelligence provides insights on how Gilead’s manufacturing strategy could position the company for success, while discussing likely US and EU approvals for Yescarta in 2L LBCL.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

FDA Approves an Updated Label for Yescarta to Include Prophylactic Corticosteroids Use

On Monday, January 31, Gilead (Kite) announced (press release) that the FDA has approved Yescarta’s (CD19 CAR-T) updated prescribing information to include the use of prophylactic corticosteroids across all approved indications. Of note, the label update is based on results from Cohort 6 of the Ph1/2 ZUMA-1 trial in r/r DLBCL. Below, Celltelligence provides insights on Yescarta’s updated US label, while discussing how it could facilitate Yescarta’s administration in the outpatient setting.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

CHMP Adopts Positive Opinion for BMS’s Breyanzi in ≥3L R/R DLBCL

On Friday, January 28, the CHMP meeting highlights were released following Monday’s CHMP agenda. Of note, the CHMP adopted (press release) a positive opinion for Breyanzi’s (liso-cel; BMS’s CD19 CAR-T) marketing authorization in ≥3L r/r DLBCL, PMBCL, and FL grade 3B. Below, Celltelligence provides thoughts on Breyanzi’s positive CHMP opinion, while comparing Breyanzi’s regulatory EU timeline with other commercialized CAR-Ts.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Adaptimmune Appoints Cintia Piccina as Chief Commercial Officer

On Wednesday, January 26, Adaptimmune announced (press release) the appointment of Cintia Piccina as Chief Commercial Officer (CCO), effective January 31, 2022. Below, Celltelligence provides insights on how Piccina’s experience may position afami-cel (MAGE-A4 SPEAR-T; formerly ADP-A2M4) for a successful commercial launch.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Carvykti’s FDA Approval Anticipated Around February 28, 2022; JNJ Q4 2021 Earnings Call Summary

On Tuesday, January 25, JNJ held their Q4 and FY 2021 earnings call (press release / presentation) highlighting Carvykti’s (BCMA CAR-T; cilta-cel) anticipated FDA approval around February 28, 2022. Below, Celltelligence provides insights on how JNJ may leverage Carvykti’s best-in-class profile to quickly gain market share following launch.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Could Breyanzi Receive a Positive CHMP Opinion This Week? Tecartus Continues to Experience Delays; January’s CHMP Agenda

On Monday, January 24, the CHMP agenda for January was released. Of note, Breyanzi (BMS’s CD19 CAR-T) is listed under the ‘Opinions’ section. No other key cell therapy-related updates were observed. Below, Celltelligence provides insights on the potential EU approval timeline for Breyanzi, while discussing regulatory timelines for Kymriah and Yescarta in r/r FL, Tecartus in r/r adult ALL, and Carvykti in r/r MM.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Abecma Approved in Japan; Can BMS Meet the Increased Manufacturing Demand? Novartis and Pack Health Explore Digital Coaching to Improve Quality of Life Outcomes Following CAR-T Treatment

On Thursday, January 20, BMS announced (press release) that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Abecma (BCMA CAR-T) for the treatment of ≥4L r/r MM. Moreover, a new clinical study evaluating the feasibility of a Digital Health Coaching Program for individuals who have received CAR-T therapy was observed on CT.gov. Of note, Pack Health is the sponsor of the trial with Novartis and Ohio State University Comprehensive Cancer Center appearing as collaborators. Below, Celltelligence provides insights on Abecma’s potential market access in Japan, while commenting on how the current viral vector shortage could limit BMS’s ability to deliver Abecma in Japan.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.